$PBYI
PUMA BIOTECHNOLOGY, INC.

2014 Form 10-K Financial Statement

#000156459015001193 Filed on March 02, 2015

View on sec.gov

Income Statement

Concept 2014 2013 Q4 2013
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $19.40M $2.980M $9.800M
YoY Change 97.96% -78.2% -58.47%
% of Gross Profit
Research & Development $122.9M $13.01M $45.05M
YoY Change 172.87% 57.13% -9.25%
% of Gross Profit
Depreciation & Amortization $630.0K $120.0K $420.0K
YoY Change 50.0% 50.0% 55.56%
% of Gross Profit
Operating Expenses $122.9M $15.99M $54.83M
YoY Change 124.17% -27.15% -26.35%
Operating Profit -$54.83M
YoY Change -26.35%
Interest Expense $300.0K $40.00K $200.0K
YoY Change 50.0% 0.0% 100.0%
% of Operating Profit
Other Income/Expense, Net $310.0K $0.00 $174.0K
YoY Change 78.16% 77.55%
Pretax Income -$142.0M -$15.95M -$54.70M
YoY Change 159.6% -27.2% -26.48%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$142.0M -$15.95M -$54.66M
YoY Change 159.73% -27.23% -26.49%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$4.733M -$554.8K -$1.906M
COMMON SHARES
Basic Shares Outstanding 28.69M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 2013 Q4 2013
SHORT-TERM ASSETS
Cash & Short-Term Investments $141.3M $83.90M $83.90M
YoY Change 68.41% -38.94% -38.94%
Cash & Equivalents $38.50M $43.04M $43.00M
Short-Term Investments $102.8M $40.90M $40.90M
Other Short-Term Assets $6.300M $2.600M $2.600M
YoY Change 142.31% 160.0% 160.0%
Inventory
Prepaid Expenses
Receivables $1.800M $9.800M $9.800M
Other Receivables $0.00 $9.813M $0.00
Total Short-Term Assets $149.4M $96.40M $96.40M
YoY Change 54.98% -35.29% -35.3%
LONG-TERM ASSETS
Property, Plant & Equipment $2.200M $1.684M $1.700M
YoY Change 29.41% 13.86% 13.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.20M $6.300M $6.300M
YoY Change 77.78% 425.0% 425.0%
Total Long-Term Assets $13.40M $7.978M $8.000M
YoY Change 67.5% 192.56% 196.3%
TOTAL ASSETS
Total Short-Term Assets $149.4M $96.40M $96.40M
Total Long-Term Assets $13.40M $7.978M $8.000M
Total Assets $162.8M $104.4M $104.4M
YoY Change 55.94% -31.2% -31.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.00M $10.69M $10.70M
YoY Change 40.19% 2118.26% 2040.0%
Accrued Expenses $29.40M $8.579M $8.600M
YoY Change 241.86% -59.57% -59.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.40M $19.27M $19.30M
YoY Change 130.05% -11.2% -11.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.300M $1.100M $1.100M
YoY Change 18.18% 0.0% 0.0%
Total Long-Term Liabilities $1.300M $1.100M $1.100M
YoY Change 18.18% 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.40M $19.27M $19.30M
Total Long-Term Liabilities $1.300M $1.100M $1.100M
Total Liabilities $45.70M $20.39M $20.40M
YoY Change 124.02% -10.54% -10.53%
SHAREHOLDERS EQUITY
Retained Earnings -$139.3M
YoY Change
Common Stock $223.2M
YoY Change 4.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $117.0M $83.99M $84.00M
YoY Change
Total Liabilities & Shareholders Equity $162.8M $104.4M $104.4M
YoY Change 55.94% -31.2% -31.18%

Cashflow Statement

Concept 2014 2013 Q4 2013
OPERATING ACTIVITIES
Net Income -$142.0M -$15.95M -$54.66M
YoY Change 159.73% -27.23% -26.49%
Depreciation, Depletion And Amortization $630.0K $120.0K $420.0K
YoY Change 50.0% 50.0% 55.56%
Cash From Operating Activities -$77.20M -$13.58M -$55.05M
YoY Change 40.24% -45.26% 25.07%
INVESTING ACTIVITIES
Capital Expenditures $1.100M -$190.0K $624.0K
YoY Change 76.28% -51.28% -158.87%
Acquisitions
YoY Change
Other Investing Activities -$61.98M $3.490M -$40.90M
YoY Change 51.54% 25462.5%
Cash From Investing Activities -$63.28M $3.290M -$41.53M
YoY Change 52.37% -943.59% 3301.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $129.4M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 136.0M 2.070M 2.215M
YoY Change 6038.6% -98.4% -98.29%
NET CHANGE
Cash From Operating Activities -77.20M -13.58M -55.05M
Cash From Investing Activities -63.28M 3.290M -41.53M
Cash From Financing Activities 136.0M 2.070M 2.215M
Net Change In Cash -4.510M -8.220M -94.36M
YoY Change -95.22% -107.9% -212.3%
FREE CASH FLOW
Cash From Operating Activities -$77.20M -$13.58M -$55.05M
Capital Expenditures $1.100M -$190.0K $624.0K
Free Cash Flow -$78.30M -$13.39M -$55.67M
YoY Change 40.65% -45.17% 29.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
9813000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2635000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
96396000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1215000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1214000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24814000
CY2012 us-gaap Operating Expenses
OperatingExpenses
74450000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
54372000
CY2013Q4 us-gaap Liabilities
Liabilities
20387000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock
ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
835000
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
129214000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
223232000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
83987000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19271000
CY2013Q4 us-gaap Assets
Assets
104374000
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1116000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10692000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8579000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104374000
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-139251000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28991289
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49636000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1684000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
5080000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28991289
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-142063000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1408000
CY2012 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
18222000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
45000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
128909000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7519000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2215000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
39151000
CY2014 pbyi Stock Issued During Period Value Stock Options Exercised And Amount Receivable
StockIssuedDuringPeriodValueStockOptionsExercisedAndAmountReceivable
6533000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
129440000
CY2012 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
16.00
CY2014 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
122.50
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
627000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
423000
CY2014 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-192000
CY2012 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-464000
CY2014 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
39151000
CY2013 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
7519000
CY2012 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
18222000
CY2014 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-8053000
CY2013 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-799000
CY2012 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
10612000
CY2014 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
8584000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4305000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
20865000
CY2014 us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
-153000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-77203000
CY2014 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
1100000
CY2013 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
624000
CY2012 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
591000
CY2014 us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
192000
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1000
CY2014 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
132259000
CY2014 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
70277000
CY2013 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
8446000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-63275000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-41531000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1221000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
129440000
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
129214000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6533000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2215000
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
45000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
135973000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2215000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
129259000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4505000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-94364000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
84026000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
137408000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53382000
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
159.62
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
67.08
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
17.12
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
89.55
CY2014Q4 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice
127.69
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.25
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates: </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and reported amounts of expenses for the period presented. Accordingly, actual results could differ from those estimates. Significant estimates include accrued expenses for the cost of services provided by consultants who manage clinical trials and conduct research and clinical trials on behalf of the Company that are billed on a delayed basis. As the actual costs become known, the Company adjusts its estimated cost in that period. The value of stock-based compensation includes estimates based on future events which are difficult to predict. It is at least reasonably possible that a change in the estimates used to record accrued expenses and to value the stock-based compensation will occur in the near term. </p></div>
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk: </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents. The Company&#8217;s cash and cash equivalents in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at December&#160;31, 2014, were approximately $39.7 million. The Company does not believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. Pursuant to the Company&#8217;s internal investment policy, investments must be rated A-1/P-1 or better by Standard and Poor&#8217;s Corporation and Moody&#8217;s Investor Services at the time of purchase. </p></div>
CY2014Q4 pbyi Common And Preferred Stock Shares Authorized Before Amendment
CommonAndPreferredStockSharesAuthorizedBeforeAmendment
110000000
CY2014Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
39700000
CY2013 us-gaap Cost Of Reimbursable Expense
CostOfReimbursableExpense
16400000
CY2012 us-gaap Cost Of Reimbursable Expense
CostOfReimbursableExpense
10600000
CY2014 pbyi License Agreement Period To Review Invoice And Supporting Documentation
LicenseAgreementPeriodToReviewInvoiceAndSupportingDocumentation
P60D
CY2014 pbyi License Agreement Expenses
LicenseAgreementExpenses
0
CY2014Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2013Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2604224
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4022584
CY2014Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
16299000
CY2013Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
7715000
CY2014Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1217000
CY2013Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
914000
CY2014Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
848000
CY2013Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
513000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3482000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2383000
CY2014Q4 pbyi Accrued Development Costs
AccruedDevelopmentCosts
7764000
CY2013Q4 pbyi Accrued Development Costs
AccruedDevelopmentCosts
4801000
CY2014Q4 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
2541000
CY2013Q4 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
2369000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
195000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
84000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2449000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1066000
CY2014Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
16414000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
81000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
259000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1325000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
699000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
1.00
CY2011Q4 pbyi Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P10Y
CY2014 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2021-04-10
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
18200000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
7519000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
19630000
CY2012 pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
0.90
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1278000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
30000
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
11666
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1906334
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1032375
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
19862
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
314623
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2604224
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1980208
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
175816
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
430490
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3978126
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2591565
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1386561
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.48
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.75
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.75
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.93
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
44.77
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.60
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.29
CY2014 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y3M18D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2014 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P9Y2M12D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
23525000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
208902000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
74109000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
431635000
CY2014Q4 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue
194498000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
237137000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
29.94
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.38
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1838633
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1051460
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
175816
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
20.18
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
17.85
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
46.48
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
81.33
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
28411
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
4964
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
4505
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
18942
CY2014 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
83808000
CY2014Q4 pbyi Deferred Tax Assets Business Credit Carryforward
DeferredTaxAssetsBusinessCreditCarryforward
9928000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
217000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
14268000
CY2014Q4 pbyi Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
128000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
84000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
108433000
CY2014Q4 pbyi Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
108433000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
108433000
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
41757000
CY2013Q4 pbyi Deferred Tax Assets Business Credit Carryforward
DeferredTaxAssetsBusinessCreditCarryforward
5052000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
234000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
11472000
CY2013Q4 pbyi Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
49000
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
85000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
58649000
CY2013Q4 pbyi Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
58649000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
58649000
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
49800000
CY2014 pbyi Operating Loss Carryforwards Expiration Dates Federal
OperatingLossCarryforwardsExpirationDatesFederal
2031
CY2014 pbyi Operating Loss Carryforwards Expiration Dates State
OperatingLossCarryforwardsExpirationDatesState
2031
CY2014 pbyi Deferred Tax Asset Increase Decrease In Equity
DeferredTaxAssetIncreaseDecreaseInEquity
42000000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-48268000
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-8465000
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
9956000
CY2014 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-3007000
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
49784000
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
23338000
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
29213000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1263000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
205000
CY2014 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
205000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1424000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1058000
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
205000
CY2014Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2012Q4 pbyi Area Of Leased Property
AreaOfLeasedProperty
13250
CY2013Q4 pbyi Area Of Leased Property
AreaOfLeasedProperty
16750
CY2014Q1 pbyi Area Of Leased Property
AreaOfLeasedProperty
22775
CY2014Q2 pbyi Area Of Leased Property
AreaOfLeasedProperty
9560
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1441000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1519000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1564000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1611000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
308000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
6443000
CY2014Q4 pbyi Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
187500000
CY2014Q4 us-gaap Contractual Obligation
ContractualObligation
96909000
CY2014Q4 pbyi Potential Milestone Payments
PotentialMilestonePayments
16500000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-19794000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-38844000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-35844000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-47483000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19794000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38844000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35844000
CY2014Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47483000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.29
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.19
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.57
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29567071
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30117819
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30117819
CY2014Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30232718
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-15946000
CY2013Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15946000
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
CY2013Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28750382
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-21913000
CY2012Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21913000
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.83
CY2012Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26511141

Files In Submission

Name View Source Status
0001564590-15-001193-index-headers.html Edgar Link pending
0001564590-15-001193-index.html Edgar Link pending
0001564590-15-001193.txt Edgar Link pending
0001564590-15-001193-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g201503021821181961866.jpg Edgar Link pending
pbyi-10k_20141231.htm Edgar Link pending
pbyi-20141231.xml Edgar Link completed
pbyi-20141231.xsd Edgar Link pending
pbyi-20141231_cal.xml Edgar Link unprocessable
pbyi-20141231_def.xml Edgar Link unprocessable
pbyi-20141231_lab.xml Edgar Link unprocessable
pbyi-20141231_pre.xml Edgar Link unprocessable
pbyi-ex105d_20141231530.htm Edgar Link pending
pbyi-ex211_201412316.htm Edgar Link pending
pbyi-ex231_20141231445.htm Edgar Link pending
pbyi-ex311_20141231498.htm Edgar Link pending
pbyi-ex312_20141231497.htm Edgar Link pending
pbyi-ex321_20141231496.htm Edgar Link pending
pbyi-ex322_20141231495.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending